Active substance
Ceftizoxime
- SFDA 5
- US FDA 4
SFDA Saudi Arabia — SFDA human drug list
| Trade name | Strength | Form · route | Pack | Public price | Type | Company | Status |
|---|---|---|---|---|---|---|---|
| CEFIZOX 1000 VIAL I-V | 1 g | Injection · Intravenous use | 1 Vial | SAR 30.35 | Generic · Prescription | Hikma Pharmaceuticals PLC | Valid |
| CEFIZOX 1000MG I-M VIAL+SOLV 0.5%LIDOCAI | 1000 mg | Powder and solvent for solution for injection · Intramuscular use | 1 Vial | SAR 30.35 | Generic · Prescription | Hikma Pharmaceuticals PLC | Withdrawn by MAH · Not Marketed |
| CEFIZOX 2000 VIAL | 2 g | Solution for injection · Intravenous use | 1 Vial | SAR 56.00 | NCE · Prescription | Hikma Pharmaceuticals PLC | Withdrawn by MAH · Not Marketed |
| CEFIZOX 500 VIAL I-V | 500 mg | Injection · Intravenous use | 1 Vial | SAR 19.05 | NCE · Prescription | Hikma Pharmaceuticals PLC | Withdrawn by MAH · Not Marketed |
| CEFIZOX 500MG I-M VIAL+SOLV 0.5%LIDOCAIN | 500 mg | Powder and solvent for solution for injection · Intramuscular use | 1 Vial | SAR 19.05 | Generic · Prescription | Hikma Pharmaceuticals PLC | Withdrawn by MAH · Not Marketed |
Indications — CHI Daman Drug Formulary
ACUTE PANCREATITIS; MUCOPURULENT CONJUCTIVITIS - GONOCOCCAL INFECTION OF THE EYE; OSTEOMYELITIS; PELVIC INFLAMMATORY DISEASE; RECURRENT URINARY TRACT INFECTIONS (UTI)
US FDA United States — FDA approvals (Drugs@FDA)
| Product | Strength | Form · route | Applicant | Status | First approved |
|---|---|---|---|---|---|
| CEFIZOX | EQ 500MG BASE/VIAL; EQ 1GM BASE/VIAL; EQ 2GM BASE/VIAL; EQ 10GM BASE/VIAL | injectable · injection | ASTELLAS | Discontinued | 15 Sep 1983 |
| CEFIZOX IN DEXTROSE 5% IN PLASTIC CONTAINER | EQ 20MG BASE/ML; EQ 40MG BASE/ML | injectable · injection | ASTELLAS | Discontinued | 3 Oct 1984 |
| CEFIZOX IN PLASTIC CONTAINER | EQ 20MG BASE/ML; EQ 40MG BASE/ML | injectable · injection | ASTELLAS | Discontinued | 3 Oct 1984 |
| CEFIZOX | EQ 1GM BASE/VIAL; EQ 2GM BASE/VIAL | injectable · injection | ASTELLAS | Discontinued | 31 Mar 1994 |
Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.